Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour

Clin Endocrinol (Oxf). 1997 Mar;46(3):373-5. doi: 10.1046/j.1365-2265.1997.1090921.x.


Hypercalcaemia, a common complication of malignancy, may result from either the lytic effect of multiple osseous metastases or the effect of tumour-derived humoral factors. Excessive secretion of parathyroid hormone-related peptide (PTHrP), a major cause of humoral hypercalcaemia of malignancy, has been incriminated as the cause of hypercalcaemia in patients with lung, breast, renal, head and neck and, occasionally, haematological malignancies. Carcinoid tumours, while frequently the source of ectopic hormone secretion, are infrequently associated with hypercalcaemia. We report the case of a 59-year-old woman with fulminant hypercalcaemia due to excessive PTHrP secretion from a hepatic carcinoid and we present the change in her serum PTHrP concentrations during infusion of a somatostatin analogue.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use
  • Carcinoid Tumor / blood
  • Carcinoid Tumor / drug therapy
  • Carcinoid Tumor / metabolism*
  • Female
  • Humans
  • Hypercalcemia / blood
  • Hypercalcemia / drug therapy
  • Hypercalcemia / etiology*
  • Liver Neoplasms / blood
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / metabolism*
  • Middle Aged
  • Neoplasm Proteins / blood
  • Neoplasm Proteins / metabolism*
  • Octreotide / therapeutic use
  • Parathyroid Hormone*
  • Parathyroid Hormone-Related Protein
  • Proteins / metabolism*
  • Somatostatin / analogs & derivatives


  • Antineoplastic Agents, Hormonal
  • Neoplasm Proteins
  • PTHLH protein, human
  • Parathyroid Hormone
  • Parathyroid Hormone-Related Protein
  • Proteins
  • Somatostatin
  • Octreotide